Zobrazeno 1 - 10
of 59
pro vyhledávání: '"François, Davodeau"'
Autor:
Floriane Etienne, Maxime Berthaud, Frédérique Nguyen, Karine Bernardeau, Catherine Maurel, Caroline Bodet-Milin, Maya Diab, Jérôme Abadie, Valérie Gouilleux-Gruart, Aurélien Vidal, Mickaël Bourgeois, Nicolas Chouin, Catherine Ibisch, François Davodeau
Publikováno v:
Frontiers in Oncology, Vol 10 (2020)
Antibodies directed against CD22 have been used in radioimmunotherapy (RIT) clinical trials to treat patients with diffuse large B-cell lymphoma (DLBCL) with promising results. However, relevant preclinical models are needed to facilitate the evaluat
Externí odkaz:
https://doaj.org/article/7e71b67d23e4426780eb2e53d47f0a08
Autor:
Jean-Baptiste Gorin, Jérémie Ménager, Sébastien Gouard, Catherine Maurel, Yannick Guilloux, Alain Faivre-Chauvet, Alfred Morgenstern, Frank Bruchertseifer, Michel Chérel, François Davodeau, Joëlle Gaschet
Publikováno v:
Neoplasia: An International Journal for Oncology Research, Vol 16, Iss 4, Pp 319-328 (2014)
Radioimmunotherapy (RIT) is a therapeutic modality that allows delivering of ionizing radiation directly to targeted cancer cells. Conventional RIT uses β-emitting radioisotopes, but recently, a growing interest has emerged for the clinical developm
Externí odkaz:
https://doaj.org/article/256472fb83534cd293b09b0b436d237a
Autor:
Laëtitia Dorso, Edith Bigot-Corbel, Jérôme Abadie, Maya Diab, Sébastien Gouard, Frank Bruchertseifer, Alfred Morgenstern, Catherine Maurel, Michel Chérel, François Davodeau
Publikováno v:
PLoS ONE, Vol 11, Iss 3, p e0151330 (2016)
Short-term toxicological evaluations of alpha-radioimmunotherapy have been reported in preclinical assays, particularly using bismuth-213 (213Bi). Toxicity is greatly influenced not only by the pharmacokinetics and binding specificity of the vector b
Externí odkaz:
https://doaj.org/article/6b9082b483f14a40be2de1e420330e30
Autor:
Jérémie Ménager, Jean-Baptiste Gorin, Catherine Maurel, Lucile Drujont, Sébastien Gouard, Cédric Louvet, Michel Chérel, Alain Faivre-Chauvet, Alfred Morgenstern, Frank Bruchertseifer, François Davodeau, Joëlle Gaschet, Yannick Guilloux
Publikováno v:
PLoS ONE, Vol 10, Iss 6, p e0130249 (2015)
Ionizing radiation induces direct and indirect killing of cancer cells and for long has been considered as immunosuppressive. However, this concept has evolved over the past few years with the demonstration that irradiation can increase tumor immunog
Externí odkaz:
https://doaj.org/article/b3759baf927d447e88b80403dbb76309
Autor:
François Davodeau, Joëlle Gaschet, Clément Bailly, Mickaël Bourgeois, Alain Faivre-Chauvet, Michel Chérel, Nicolas Chouin, Caroline Bodet-Milin, François Guérard, Françoise Kraeber-Bodéré
Publikováno v:
Nuclear Medicine Therapy
Nuclear Medicine Therapy, 2019, ⟨10.1007/978-3-030-17494-1_8⟩
Nuclear Medicine Therapy ISBN: 9783030174934
Nuclear Medicine Therapy, 2019, ⟨10.1007/978-3-030-17494-1_8⟩
Nuclear Medicine Therapy ISBN: 9783030174934
Lymphomas are a diverse range of hematologic tumors that arise from cells of the immune system. This chapter discusses recent available clinical data on the use of radioimmunotherapy (RIT) to treat this indication. RIT is a targeted therapy where rad
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a11b97a88430829a5e0f308355df88ba
https://www.hal.inserm.fr/inserm-02309716
https://www.hal.inserm.fr/inserm-02309716
Autor:
François Davodeau, Caroline Rousseau, Joëlle Gaschet, Jérôme Abadie, Catherine Ibisch, E. Verger, M. Berthaud, Catherine Maurel, F. Nguyen, M. Diab, Michel Chérel
Publikováno v:
Veterinary and Comparative Oncology. 15:932-951
We isolated 11 antibodies specific for canine CD138 (cCD138) to validate the interest of CD138 antigen targeting in dogs with spontaneous mammary carcinoma. The affinity of the monoclonal antibodies in the nanomolar range is suitable for immunohistoc
Autor:
Sébastien Gouard, Benjamin Chalopin, Catherine Saï-Maurel, François Guérard, Laurent Navarro, jean-françois GESTIN, Nicolas Chouin, Ferid Haddad, Cyrille Alliot, Françoise Kraeber-Bodéré, François Davodeau, Michel Chérel
Publikováno v:
European Journal of Nuclear Medicine and Molecular Imaging
EANM 2018: 31st Annual Congress of the European Association of Nuclear Medicine
European Journal of Nuclear Medicine and Molecular Imaging, Springer Verlag (Germany), 2018, 45 (1), pp.S166-S167
Publons
Web of Science
HAL
European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45 (1), pp.S166-S167
EANM 2018: 31st Annual Congress of the European Association of Nuclear Medicine
European Journal of Nuclear Medicine and Molecular Imaging, Springer Verlag (Germany), 2018, 45 (1), pp.S166-S167
Publons
Web of Science
HAL
European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45 (1), pp.S166-S167
s of Annual Congress of the European Association of Nuclear Medicine October 13 – 17, 2018 Düsseldorf, Germany; International audience; Aim: Multiple myeloma is a B-cell malignancy of terminally differentiated plasma cells within the bone marrow.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::5bdf0d50705d203b648e1517a1b47162
https://www.hal.inserm.fr/inserm-02341491/document
https://www.hal.inserm.fr/inserm-02341491/document
Autor:
Michel Chérel, Jacques Barbet, Joëlle Gaschet, Jean-François Gestin, Amandine Pallardy, Thomas Carlier, François Davodeau, Alain Faivre-Chauvet, Françoise Kraeber-Bodéré, Caroline Rousseau, Caroline Bodet-Milin, Ludovic Ferrer, T. Eugène, Eric Frampas
Publikováno v:
Seminars in Oncology. 41:613-622
Radioimmunotherapy (RIT) has been developed for more than 30 years. Two products targeting the CD20 antigen are approved in the treatment of non-Hodgkin B-cell lymphoma (NHBL): iodine 131-tositumomab and yttrium 90-ibritumomab tiuxetan. RIT can be in
Autor:
Joëlle Gaschet, Alain Faivre-Chauvet, A. Pallardy, Catherine Maurel, François Davodeau, E. Matous, F. Kraeber-Bodéré, Frank Bruchertseifer, Michel Chérel, Alfred Morgenstern, Sébastien Gouard
Publikováno v:
Nuclear Medicine and Biology. 41:e30-e35
Introduction Multiple myeloma (MM) is a B-cell malignancy of terminally differentiated plasma cells within the bone marrow. Despite intense research to develop new treatments, cure is almost never achieved. Alpha-radioimmunotherapy (RIT) has been sho
Autor:
Jérémie, Ménager, Jean-Baptiste, Gorin, Nolwenn, Fichou, Sébastien, Gouard, Alfred, Morgenstern, Frank, Bruchertseifer, François, Davodeau, Françoise, Kraeber-Bodéré, Michel, Chérel, Joëlle, Gaschet, Yannick, Guilloux
Publikováno v:
Medecine sciences : M/S. 32(4)
Alpha-radioimmunotherapy (α-RIT) is a targeted anti-tumor therapy using usually a monoclonal antibody specific for a tumor antigen that is coupled to an α-particle emitter. α-emitters represent an ideal tool to eradicate disseminated tumors or met